Full-stack wearables are the future.
Gameplan. WHOOP CEO Will Ahmed told Bloomberg the company is weighing an IPO within two years as it evolves into a medical-grade health platform — adding ECG, blood pressure, AFib detection, and integrated bloodwork.
In-sync. Following smart ring makers Oura and Ultrahuman, WHOOP plans to integrate CGM data while exploring sensors to bring noninvasive, continuous glucose tracking directly into the device.
Platform play. Beyond the wrist-worn tracker, WHOOP is expanding Advanced Labs with new biomarker panels spanning hormones, heart health, and metabolism. Pushing toward prediction, it’s training an AI model to forecast health events the same way LLMs predict words.
Scaling up, the company’s international footprint now accounts for 60% of sales, and rising interest in longevity-focused insights is accelerating adoption among non-athletes.
Punchline: As hardware, biomarkers, and AI converge, WHOOP is positioning itself as a Personal Health OS, tapping growing demand for continuous, proactive well-being.
